Skip to main content

Table 4 Effect of each parameter on OS according to baseline values and to the variation between T1 value (after 1 month of therapy) and T0 value (baseline value). This difference has been indicated as delta value (Δ)

From: Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma

Parameter Univariate Two-variable Multivariablea
Variable Timepoint Value p HR Lower HR Upper HR p HR Lower HR Upper HR p HR Lower HR Upper HR
Platelets Basal  + 10,000      0.041 1.020 1.001 1.039 – – – –
Δ Ref ≤ 25,000      0.022 1.512 1.063 2.151 – – – –
White blood cell count Basal  + 100       < 0.001 1.009 1.005 1.013 – – – –
Δ Ref ≤ 1920       < 0.001 3.246 2.171 4.854  < 0.001 2.918 1.882 4.526
Neutrophils Basal  + 100       < 0.001 1.014 1.010 1.018  < 0.001 1.011 1.005 1.016
Δ Ref ≤ 310       < 0.001 1.880 1.330 2.659 – – – –
Lymphocytes Basal  + 100      0.045 0.977 0.955 0.999 – – – –
Δ Ref ≥ -300       < 0.001 2.319 1.578 3.409 0.038 1.627 1.028 2.576
NL ratio Basal  + 1       < 0.001 1.279 1.169 1.400 – – – –
Δ Ref ≤ 0.86       < 0.001 2.908 2.012 4.202 – – – –
PL ratio Basal  + 1      0.006 1.003 1.001 1.005 0.022 1.003 1.000 1.005
Δ Ref ≤ 22.85       < 0.001 2.019 1.429 2.853 0.140 1.378 0.901 2.109
Age Basal  + 1 0.255 1.008 0.994 1.021      – – – –
Sex Basal Ref F 0.282 0.829 0.589 1.166      – – – –
Number of metastatic sites Basal Ref ≥ 3 0.089 0.746 0.532 1.046      – – – –
LDH Basal Ref elevated  < 0.001 0.395 0.276 0.564       < 0.001 0.499 0.344 0.724
  1. Statistically significant values in bold
  2. At the Δ timepoint the variables have been dichotomized and the “value” represents the reference category
  3. HR (hazard ratio) values are expressed in terms of risk of mortality
  4. aAfter stepwise selection
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us